# Cigna Group Moat

Status: published. Policy: company-analysis-1.

Cigna demonstrates substantial operations, profitable execution and large-client contract renewals or extensions, but the passages do not establish durable switching costs, network effects, differentiated assets or relative cost advantages. PBM price reductions and increased rebate sharing demonstrate weak realized pricing power. Clinical capabilities and integrated services remain possible sources of advantage rather than demonstrated moats. The rebate-free transition has no demonstrated durable economic outcome here. Persistent client losses despite concessions, or sustained deterioration in contract economics after recontracting, would invalidate a future moat thesis. Evidence of durable customer persistence and relative cost benefits through these changes would support reconsideration.

- [https://www.sec.gov/Archives/edgar/data/1739940/000173994026000006/ci-20251231.htm](https://www.sec.gov/Archives/edgar/data/1739940/000173994026000006/ci-20251231.htm) · 2026-02-26
- [https://www.sec.gov/Archives/edgar/data/1739940/000173994026000065/ci-20260630.htm](https://www.sec.gov/Archives/edgar/data/1739940/000173994026000065/ci-20260630.htm) · 2026-07-30
- [https://www.sec.gov/Archives/edgar/data/1739940/000173994026000023/ci-20260312.htm](https://www.sec.gov/Archives/edgar/data/1739940/000173994026000023/ci-20260312.htm) · 2026-03-13
- [https://www.sec.gov/Archives/edgar/data/1739940/000173994025000009/ci-20241231.htm](https://www.sec.gov/Archives/edgar/data/1739940/000173994025000009/ci-20241231.htm) · 2025-02-27
- [https://www.sec.gov/Archives/edgar/data/1739940/000173994024000005/ci-20231231.htm](https://www.sec.gov/Archives/edgar/data/1739940/000173994024000005/ci-20231231.htm) · 2024-02-29
- [https://www.sec.gov/Archives/edgar/data/1739940/000173994026000043/ci-20260331.htm](https://www.sec.gov/Archives/edgar/data/1739940/000173994026000043/ci-20260331.htm) · 2026-04-30

[JSON](https://beanvest.com/stock/ci/moat.json)